Sanofi: EMA recommendation for sleeping sickness drug

(CercleFinance.com) - Sanofi announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended fexinidazole, the first all-oral treatment for sleeping sickness.


This opinion is based on clinical trials conducted by the Drugs for Neglected Diseases Initiative (DNDi), a non-profit research and development organsation that paves the way for the distribution of this product in 2019, in countries where this disease is endemic.

Human sleeping sickness or human trypanosomiasis is transmitted by the bite of an infected tsetse fly and is characterised by neuropsychiatric symptoms. About 65 million people are at risk of being infected by this disease in sub-Saharan Africa.



Copyright (c) 2018 CercleFinance.com. All rights reserved.